🛑هااام 🛑

للطلاب الملتحقين في دورات الإسعافات الأولية نحيطكم علما أن الدورة سوف تبدأ من يوم الأربعاء2021/1/27 .
المكان : كلية الطب
الزمان : من الساعة 2 الى الساعة 4 فترة مسائية .
_- _ - _- _ - _

{ مع تمنياتنا للجميع بالتوفيق والنجاح  }

#الفريق_الطبي_اليمني_فرع إب
#ملتقى_الطالب_الجامعي.

ہـ٨ــہہـــ🚑ہہــ٨ــہہــ٨ـــہــہہـ٨ــہہــ

📲للتواصل والإستفسار عبر رسائل الواتساب او التلبجرام 773530658 او عبر بوت التليجرام @YMTIBot

-قناتنا على تلجرام:
https://www.tg-me.com/joinchat-AAAAAE-cWdYJS9FEAKV7Xg
-صفحتنا على الفيسبوك:
https://www.facebook.com/101655188380876/posts/
-القناة المركزية للفريق :
T.me/joinchat-AAAAAE-nMiVep-7bC9vxMg

💥موعدنا الاسبوع القادم في دورة:

*📌" دلالات وتفسير النتائج المخبرية"📍*

مع الدكتور / عبدالرحمن زباد

مدرب متمكن... خبرة 20 عام
تدريب بطريقة رائعة.

🔰محاور الدورة:- (موضح بالصورة).

💥مميزات الدورة:
⚡️ مناقشة جميع المحاور من الناحية العلمية والطبية والتطبيقية.
⚡️الشهادة صادرة باللغتين العربية والإنجليزية ومعتمدة من المركز الطبي الاكاديمي للتدريب والتطوير
⚡️يتم استلام الشهادة في اخر يوم من الدورة.

🕰مـدة الدورة : 4 ايام بمعدل ثلاث ساعات يومياً
-فترة صباحية : من الساعة 9 وحتى 12 ساعة

🔹رسوم الدورة : فقط 5000 ريال وشاملة المادة التدريبية والشهادة وكافة المميزات.

💡💡💡💡💡💡💡💡
للتسجيـــل والحجـــز قبل اكتمال العدد
عبر زيارتنا للمركز الطبي الأكاديمي مقابل البوابة الشمالية لجامعة صنعاء الجديدة جوار جامعة العلوم والتكنولوجيا فرع الطالبات.
او يتم ارســـــال كلمــــة (تحاليل مخبرية) + الإسم مع الجامعة والتخصص الى الرقم 778919528 عبر الواتساب او التلجرام .
للتسجيل مباشره عبر رابط الواتساب:
http://wa.me/967778919528

#المركز_الطبي_الاكاديمي
#جودة_التعليم_الطبي
؛_________________________

Answer\

🖤C:Immediately on lying flat

Tetralogy of Fallot (TOF) is a congenital heart defect with four components:
1) Pulmonary stenosis, narrowing of the exit from the right ventricle
2) A ventricular septal defect, a hole between the two ventricles
3) Right ventricular hypertrophy, thickening of the right ventricular muscle
4) An overriding aorta, which allows blood from both ventricles to enter the aorta

المركز الطبي الأكاديمي للتدريب والتطوير
Academic Medical Center For Training & Development
👈هو أول المراكز الأكاديمية الناشئة والمتفرعة من مؤسسة الفريق الطبي اليمني Yemeni Medical Team بإدارة مستقلة.

👁رؤيتنا:
الريادة والتميز في مجال التعليم الطبي والتطبيقي وخدمة المجتمع.

🔰رسالتنا: المساهمة في إعداد كادر طبي بكفاءة عالية ذوي مهارات ومعلومات قيمة قادرين على أداء مهنتهم المقدسة بصورة فعالة في المجتمع.

♻️اهدافنا:
1- تدريس المعلومات الطبية الحديثة وتطوير المهارات والمواقف لجعل الكادر الطبي قادر على إدارة مختلف الحاجات الصحية للمجتمع في مختلف المجالات الطبية.
2- المساهمة في تطوير معايير ومهارات التدريس بواسطة التعليم و التدريب الطبي المستمر من خلال ورشات العمل والمؤتمرات.
3- المشاركة في العمل على تطوير وبناء بحوث طبية عالية المستوى في مختلف المجالات الطبية ونشرها.

🏢موقعنا: مقابل البوابة الشمالية لجامعة صنعاء الجديدة.

☎️📲ارقام التواصل الخاصة بالمركز:
01380102 , 778919528 , 778867597
📩البريد الالكتروني:
[email protected]
🔺 القناة المركزية للفريق الطبي اليمني:-
T.me/YemeniMedicalTeam

🔰Axi-cel for Relapsed or Refractory Large B-Cell Lymphoma🔰

♦️BACKGROUND:-
The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor.

♦️METHODS:-
In this international, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with large B-cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy to receive axicabtagene ciloleucel (axi-cel, an autologous anti-CD19 chimeric antigen receptor T-cell therapy) or standard care (two or three cycles of investigator-selected, protocol-defined chemoimmunotherapy, followed by high-dose chemotherapy with autologous stem-cell transplantation in patients with a response to the chemoimmunotherapy). The primary end point was event-free survival according to blinded central review. Key secondary end points were response and overall survival. Safety was also assessed.

♦️RESULTS:-
A total of 180 patients were randomly assigned to receive axi-cel and 179 to receive standard care. The primary end-point analysis of event-free survival showed that axi-cel therapy was superior to standard care. At a median follow-up of 24.9 months, the median event-free survival was 8.3 months in the axi-cel group and 2.0 months in the standard-care group, and the 24-month event-free survival was 41% and 16%, respectively (hazard ratio for event or death, 0.40; 95% confidence interval, 0.31 to 0.51; P<0.001). A response occurred in 83% of the patients in the axi-cel group and in 50% of those in the standard-care group (with a complete response in 65% and 32%, respectively). In an interim analysis, the estimated overall survival at 2 years was 61% in the axi-cel group and 52% in the standard-care group. Adverse events of grade 3 or higher occurred in 91% of the patients who received axi-cel and in 83% of those who received standard care. Among patients who received axi-cel, grade 3 or higher cytokine release syndrome occurred in 6% and grade 3 or higher neurologic events in 21%. No deaths related to cytokine release syndrome or neurologic events occurred.

♦️CONCLUSIONS:-
Axi-cel therapy led to significant improvements, as compared with standard care, in event-free survival and response, with the expected level of high-grade toxic effects.
_______________
https://www.tg-me.com/Scientific_YMT

📌Axi-cel for Relapsed or Refractory Large B-Cell Lymphoma

لأول مـرة باليمـن افتتـاح التسجيـل فـي دورة :

🔰 Opthalmology First Aids🔰
-المـدة:- 5 سـاعـات من الساعة 9 صباحاً الى الساعة 2 بعد الظهر.
-برسـوم 15 الف ريـال شاملـة الشهـادة وكذلك شامل وجبه غذائية Breakfast .
؛__________________
🏢مكــان عقد الــدورة؛ :-
في المركز الطبــي الأكاديمي-معهد اديسون/ مقابــل البوابــة الشمالية لجامعة صنعــاء الجديدة _جــوار جامعــة العلوم والتكنولوجيــا فــرع الطالبــات - بجانـب البنك التجــاري اليمنــي.
🔻موقـــع المركــز على خرائـــط جوجــل:-
https://maps.app.goo.gl/xqfSXMrxPLHbSvG26

؛________
📲للتسجيل والحجز يرجى زيارتنـــا الى المركـــز الطبي الاكاديمـي عبــر العنــوان أعلاه.

او عبر التسجيــل المباشــر عبــر رابــط الواتســاب👇
https://api.whatsapp.com/send?phone=967778919528&text=أرغب_بالتسجيل_في_دورة_Opthalmology_First_Aids
ومن ثم ارسال الإســـم والمؤهل برسالة واحدة

📲للتواصـل والاستفسـار عبـر احـد الأرقـام التالية:-
773138973 ، 778867597
(اتصال + SMS + تليجرام او واتساب)
_للتواصل مباشرة عبر حساب التليجـرام التالي:-_
http://T.me/Academic_Medical_Center

🔰Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

♦️BACKGROUND:
Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro.

♦️METHODS:
We conducted a phase 2–3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days. Covid-19–related hospitalization or death from any cause through day 28, viral load, and safety were evaluated.

♦️RESULTS:
A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group). In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19–related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], −9.04 to −3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths. Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of −5.81 percentage points (95% CI, −7.78 to −3.84; P<0.001; relative risk reduction, 88.9%). All 13 deaths occurred in the placebo group. The viral load was lower with nirmaltrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of −0.868 log10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms. The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%). Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo.

♦️CONCLUSIONS:-
Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.
_____________________
https://www.tg-me.com/Scientific_YMT

📌Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer:

Abstract:

♦️BACKGROUND:
Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown.

♦️METHODS:
In this international, phase 3 trial, we randomly assigned patients with metastatic, hormone-sensitive prostate cancer in a 1:1 ratio to receive darolutamide (at a dose of 600 mg [two 300-mg tablets] twice daily) or matching placebo, both in combination with androgen-deprivation therapy and docetaxel. The primary end point was overall survival.

♦️RESULTS:
The primary analysis involved 1306 patients (651 in the darolutamide group and 655 in the placebo group); 86.1% of the patients had disease that was metastatic at the time of the initial diagnosis. At the data cutoff date for the primary analysis (October 25, 2021), the risk of death was significantly lower, by 32.5%, in the darolutamide group than in the placebo group (hazard ratio 0.68; 95% confidence interval, 0.57 to 0.80; P<0.001). Darolutamide was also associated with consistent benefits with respect to the secondary end points and prespecified subgroups. Adverse events were similar in the two groups, and the incidences of the most common adverse events (occurring in ≥10% of the patients) were highest during the overlapping docetaxel treatment period in both groups. The frequency of grade 3 or 4 adverse events was 66.1% in the darolutamide group and 63.5% in the placebo group; neutropenia was the most common grade 3 or 4 adverse event (in 33.7% and 34.2%, respectively).

♦️CONCLUSIONS:
In this trial involving patients with metastatic, hormone-sensitive prostate cancer, overall survival was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points. The frequency of adverse events was similar in the two groups.


___________
https://www.tg-me.com/Scientific_YMT

متجر الكتروني لبيع المستلزمات الطبية  والإلكترونية ومستلزمات طب الأسنان بأقل من اسعار السوق (اسعار وعروض مخفضة جداً)  ، ويوجد خدمة توصيل في صنعاء وشحن الى اغلب المحافظات ،،، ادخل قناة المتجر و تصفح العروض التي قد تم تنزيلها بالتأكيد ستنال اعجابك!! 👇
https://www.tg-me.com/SmartStore96

وانتظروا اقوى العروض بالايام القادمة بمناسبة قدوم شهر رمضان المبارك ،، سيتم تنزيل كافة العروض على قناة المتجر (سمارت ستور)🤩😍
🤩كذلك هناك مسابقات ستقام في القناة والجوائز عبارة عن سماعات طبية وأجهزة الفحص  وأجهزة ضغط الدم وفلاشات 2 تيرا  والعديد من عروضنا الضخمة😍